Journal
ONCOTARGET
Volume 7, Issue 8, Pages 8743-8755Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.7087
Keywords
gastric cancer; 5-Fluorouracil-based chemotherapy; gene expression; drug resistance; prognostic signature
Categories
Funding
- Natural Science Foundation of China [81372213, 81501215, 81501829, 81572935]
- Medical Elite Cultivation Program of Fujian, P.R.C [2013-ZQN-ZD-24]
Ask authors/readers for more resources
5-Fluorouracil (5-FU)-based chemotherapy is currently the first-line treatment for gastric cancer. In this study, using gene expression profiles for a panel of cell lines with drug sensitivity data and two cohorts of patients, we extracted a signature consisting of two gene pairs (KCNE2 and API5, KCNE2 and PRPF3) whose within-sample relative expression orderings (REOs) could robustly predict prognoses of gastric cancer patients treated with 5-FU-based chemotherapy. This REOs-based signature was insensitive to experimental batch effects and could be directly applied to samples measured by different laboratories. Taking this unique advantage of the REOs-based signature, we classified gastric cancer samples of The Cancer Genome Atlas (TCGA) into two prognostic groups with distinct transcriptional characteristics, circumventing the usage of confounded TCGA survival data. We further showed that the two prognostic groups displayed distinct copy number, gene mutation and DNA methylation landscapes using the TCGA multi-omics data. The results provided hints for understanding molecular mechanisms determining prognoses of gastric cancer patients treated with 5-FU-based chemotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available